Diabetes prevention: can insulin secretagogues do the job?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21185798.
- Also identified by DOI 10.1016/j.pcd.2010.11.002 and PMC identifier 3746508.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The recent Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial reported that nateglinide, a non-sulfonylurea insulin secretagogue, failed to prevent progression from impaired glucose tolerance to diabetes. In order to determine the beneficial effect of insulin secretagogues as a class in diabetes prevention, we performed a literature search for randomized controlled studies and review articles on diabetes prevention and use of sulfonylureas, nateglinide, and meglitinide in PubMed and Ovid Medline since 1950. Three studies were identified with none of them reporting success in preventing diabetes, indicating that insulin secretagogues should not be recommended for diabetes prevention.
Medical subject headings
- Blood Glucose
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Insulin
- Preventive Health Services